|
|
Enron Mail |
VIRAL GENETICS, INC.
December, 2001 HIGHLIGHTS * Viral Genetics has developed a revolutionary new technology called TNP which, based on clinical results to date, not only stops but also reverses the progression of HIV infection in people. * TNP is an extracted, naturally occurring, biologically active linear protein which, when purified and modified, greatly stimulates the body's immune response system. * Three months after an eight week TNP treatment, 8 out of 10 terminally ill AIDS patients in clinical trials show virtually no sign of HIV infection. * TNP treated patients display virtually no side effects to treatment. * TNP technology is patented in 16 countries and patent pending in Canada and the U.S. * Treatments are far less costly and less cumbersome than currently employed alternatives. OVERVIEW Viral Genetics, Inc. was founded in 1995 to develop and commercialize therapeutic and diagnostic systems for the treatment of viral diseases. Their primary focus has been on finding a treatment which would stop and reverse the progression of HIV infection in humans. After expenditures in excess of $8M, Viral Genetics developed their core technology - TNP (Thymus Nuclear Protein). Since TNP's discovery, Viral Genetics has conducted numerous animal studies and three human clinical trials. Each human trial consisted of 10 to 20 patients in the late stages of infection. TNP was administered by intra-muscular injection bi-weekly over an eight week period. Follow up was carried out on all the patients anywhere from 50 to 667 days after treatment. The trials revealed the following incredible results with respect to TNP's efficacy and safety: - HIV viral levels were reduced by 90% even 18 months after treatment. - Patients experienced minimal side effects during treatment which completely subsided after treatment and remained that way even 18 months after treatment. - Dramatic reductions occurred even with HIV resistant strains that no Antiviral Drug Cocktail has shown any efficacy with whatsoever. - Most patients started to regain body weight during and after TNP treatment. Viral Genetics is in discussions with a number of world wide governments to commercialize the TNP technology. STRUCTURE Listed: OTCBB Sy mbol: VRAL Shares Outstanding: 37.11M Public Float: 3.20M Warrants: none Op tions: none Website: www.viralgenetics.com <http://www.viralgenetics.com<; Recent Price: $1.40 Share Price High: $3.50 Share Price Low: $0.40 For further information, please contact: Alternative Capital Group (416) 601-0076
|